Compare Equinor ASA (EQNR) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Equinor ASA vs Moderna, Inc. — how do they compare? Equinor ASA trades at $40.9 (market cap $97.58B), while Moderna, Inc. trades at $63.8 (market cap $24.18B). The key difference: Equinor ASA is far larger — about 4× Moderna, Inc.'s market cap, and Equinor ASA pays a 3.81% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| EQNR | MRNA | |
|---|---|---|
Market Cap | $97.58B | $24.18B |
Sector | Energy | Health |
52-Week High | $42.40 | $81.80 |
52-Week Low | $22.41 | $22.36 |
Enterprise Value | $106.28B | $20.33B |
Dividend Yield | 3.81% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Equinor (EQNR) trades at $40.865, down 0.3% on the day, with a bullish technical signal from moving averages. The company reported mixed Q2 2026 earnings, missing EPS estimates but showing strong revenue growth of 40% year-over-year. Valuation ratios remain attractive with a P/E of 11.09 and EV/EBITDA of 2.3. Recent news highlights a 22.2% monthly rally, driven by higher energy prices and output, alongside ongoing share buybacks and consistent dividend payments.
The outlook is cautiously positive, supported by robust cash flow and strategic investments in production growth. However, risks include volatile energy prices, execution challenges in portfolio adjustments, and a high tax burden impacting net margins. Analyst sentiment is mixed, with 30% buy ratings but majority holds, reflecting valuation concerns after recent gains.
Moderna (MRNA) trades at $63.57, up 6.29% on the day, reflecting positive momentum following FDA approval of its mRNA flu vaccine, mFLUSIVA, for adults 50 and older. The stock exhibits a bullish technical outlook with moving averages supporting upward movement, though RSI levels suggest potential overbought conditions. Fundamentally, revenue has declined from pandemic peaks, with 2025 revenue at $1.92B and a net loss of -$2.82B, yet the company has beaten EPS estimates in recent quarters. Cash flow trends show improvement, with net cash flow turning positive in 2025 at $668M.
The outlook for MRNA hinges on pipeline execution beyond COVID-19, with recent vaccine approvals providing growth catalysts. Investment opportunities include diversification into flu, Ebola, and oncology therapies, but risks persist from high cash burn, competitive pressures, and reliance on successful clinical trials. Analyst sentiment is mixed with a consensus price target of $54.33, below the current price, indicating caution despite some bullish developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Equinor ASA
Equinor is a Norway-based integrated oil and gas company. It has been publicly listed since 2001, but the government retains a 67% stake. Operating primarily on the Norwegian Continental Shelf, the firm produced 2.1 million barrels of oil equivalent per day in 2021 (52% oil) and ended the year with 5.4 billion barrels of proven reserves (49% oil). Operations also include offshore wind, solar, oil refineries and natural gas processing, marketing, and trading.
Read more on EQNR →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
